背景：鼻前庭鳞状细胞癌（SCCNV）是一种罕见的疾病，在表述上明显不同，治疗,以及鼻腔和鼻旁窦鳞状细胞癌（SCC）的结果。然而,这些通常不单独分析。
方法：使用荷兰癌症登记处（NCR）和荷兰全国病理学数据库（PALGA）的病理报告来鉴定2008年至2021年间荷兰所有新诊断的SCCNV病例。
结果：共纳入763例患者。年发病率显示出显着下降趋势，年变化百分比（APC）为-3.9％。5年总生存率(OS)和无病生存率分别为69.0%和77.2%,分别。5年相对生存率为77.9%，在纳入期内略有改善。cT3分期的患者的OS似乎比cT4a分期的患者差，对TNM分类的适用性提出质疑。
结论：鼻前庭的SCC很少见，发病率下降。建议为SCCNV引入特定的拓扑代码以提高配准精度。TNM分类似乎不适用于SCCNV，这表明需要探索其他分期方法。
BACKGROUND: Squamous cell carcinoma of the nasal vestibule (SCCNV) is a rare disease, distinctly different in presentation, treatment, and outcome from squamous cell carcinoma (SCC) of the nasal cavity and paranasal sinuses. However, these are often not analyzed separately.
METHODS: The Netherlands Cancer Registry (NCR) and pathology reports from the Dutch Nationwide Pathology Databank (PALGA) were used to identify all newly diagnosed SCCNV cases in the Netherlands between 2008 and 2021.
RESULTS: A total of 763 patients were included. The yearly incidence rate displayed a significant downward trend with an annual percentage change (APC) of -3.9%. The 5-year overall survival (OS) and disease-free survival were 69.0% and 77.2%, respectively. The 5-year relative survival was 77.9% and improved slightly over the inclusion period. OS for patients who were staged cT3 appeared to be worse than those staged cT4a, calling the applicability of the TNM-classification into question.
CONCLUSIONS: SCC of the nasal vestibule is rare, with declining incidence rates. Introducing a specific topography code for SCCNV is recommended to enhance registration accuracy. The TNM classification seems poorly applicable to SCCNV, suggesting the need to explore alternative staging methods.
